DK3574922T3 - Modificerede eller polymerkonjugerede fumagillol-metap2-inhibitorer til anvendelse til forbedring eller reetablering af insulinfølsomhed - Google Patents
Modificerede eller polymerkonjugerede fumagillol-metap2-inhibitorer til anvendelse til forbedring eller reetablering af insulinfølsomhed Download PDFInfo
- Publication number
- DK3574922T3 DK3574922T3 DK19185831.5T DK19185831T DK3574922T3 DK 3574922 T3 DK3574922 T3 DK 3574922T3 DK 19185831 T DK19185831 T DK 19185831T DK 3574922 T3 DK3574922 T3 DK 3574922T3
- Authority
- DK
- Denmark
- Prior art keywords
- conjunged
- fumagillol
- polymer
- modified
- improve
- Prior art date
Links
- CEVCTNCUIVEQOY-UHFFFAOYSA-N Fumagillol Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(O)CCC21CO2 CEVCTNCUIVEQOY-UHFFFAOYSA-N 0.000 title 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 title 1
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 title 1
- CEVCTNCUIVEQOY-STXHBLNNSA-N fumagillol Chemical compound C([C@@H](O)[C@H](C1[C@]2(C)[C@H](O2)CC=C(C)C)OC)C[C@@]21CO2 CEVCTNCUIVEQOY-STXHBLNNSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361810468P | 2013-04-10 | 2013-04-10 | |
| US201461925918P | 2014-01-10 | 2014-01-10 | |
| EP14782950.1A EP2984085B1 (en) | 2013-04-10 | 2014-04-09 | Modified or polymer-conjugated fumagillol metap2 inhibitors for use in treating obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3574922T3 true DK3574922T3 (da) | 2021-12-06 |
Family
ID=51686946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14782950.1T DK2984085T3 (da) | 2013-04-10 | 2014-04-09 | Modificerede eller polymerkonjugerede fumagillol metap2-hæmmere til anvendelse i behandling af fedme |
| DK19185831.5T DK3574922T3 (da) | 2013-04-10 | 2014-04-09 | Modificerede eller polymerkonjugerede fumagillol-metap2-inhibitorer til anvendelse til forbedring eller reetablering af insulinfølsomhed |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14782950.1T DK2984085T3 (da) | 2013-04-10 | 2014-04-09 | Modificerede eller polymerkonjugerede fumagillol metap2-hæmmere til anvendelse i behandling af fedme |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US9173956B2 (enExample) |
| EP (2) | EP3574922B1 (enExample) |
| JP (5) | JP6420314B2 (enExample) |
| CN (2) | CN112494476A (enExample) |
| AU (1) | AU2014250983B2 (enExample) |
| BR (1) | BR112015025892A2 (enExample) |
| CA (1) | CA2908993C (enExample) |
| DK (2) | DK2984085T3 (enExample) |
| EA (1) | EA033912B1 (enExample) |
| ES (2) | ES2749746T3 (enExample) |
| MX (2) | MX371095B (enExample) |
| WO (1) | WO2014169026A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2576638T3 (da) * | 2010-05-25 | 2021-03-15 | Syndevrx Inc | Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| US9173956B2 (en) * | 2013-04-10 | 2015-11-03 | Syndevrx, Inc. | METAP2 inhibitors and methods of treating obesity |
| CN106432255A (zh) * | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| ES2893749T3 (es) * | 2015-12-10 | 2022-02-10 | Syndevrx Inc | Derivados de fumagilol y polimorfos de los mismos |
| CA3008960C (en) | 2016-01-11 | 2024-07-02 | Syndevrx, Inc. | TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION |
| WO2020087077A1 (en) | 2018-10-26 | 2020-04-30 | Syndevrx,Inc. | Biomarkers of metap2 inhibitors and applications thereof |
| CN114656372B (zh) * | 2020-09-14 | 2024-06-18 | 广州药本君安医药科技股份有限公司 | 对苯二胺桥连化合物及其在制备治疗糖代谢紊乱疾病的药物中的应用 |
| CN118871428A (zh) * | 2022-02-16 | 2024-10-29 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | Metap2抑制剂及其用途 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2803586A (en) | 1953-06-29 | 1957-08-20 | Abbott Lab | ph control in production of fumagillin |
| GB8500209D0 (en) * | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
| SE8702550D0 (sv) | 1987-06-18 | 1987-06-18 | Anders Grubb | Cysteinproteashemmare |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| US4997878A (en) | 1988-12-29 | 1991-03-05 | Exxon Research And Engineering Company | Hydrophobically associating polymers containing dimethyl acrylamide functionality |
| US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
| GB9320781D0 (en) | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
| US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| WO1999011272A1 (en) | 1997-09-02 | 1999-03-11 | Johns Hopkins University School Of Medicine | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
| WO1999039702A2 (en) | 1997-10-31 | 1999-08-12 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
| US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
| KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| AU3733399A (en) | 1998-05-22 | 1999-12-13 | Daiichi Pharmaceutical Co., Ltd. | Drug composites |
| US6464850B1 (en) | 1998-07-31 | 2002-10-15 | Biowhittaker Molecular Applications, Inc. | Method for producing hydrophilic monomers and uses thereof |
| CN1191093C (zh) | 1998-10-30 | 2005-03-02 | 第一制药株式会社 | Dds化合物及其测定方法 |
| JP4883515B2 (ja) | 1999-09-08 | 2012-02-22 | ポリセリックス リミテッド | 均一分子量ポリマー |
| US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
| US20070161570A1 (en) * | 2000-11-01 | 2007-07-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| ATE440094T1 (de) | 2001-09-27 | 2009-09-15 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
| US20060099660A1 (en) | 2002-02-15 | 2006-05-11 | Synovo Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| AU2003230852B2 (en) | 2002-04-11 | 2008-07-10 | Children's Medical Center Corporation | TNP-470 polymer conjugates and use thereof |
| US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
| US20040116348A1 (en) | 2002-09-23 | 2004-06-17 | Ying Chau | Polymer-linker-drug conjugates for targeted drug delivery |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| US20040228831A1 (en) * | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
| CN102989009B (zh) | 2003-12-31 | 2015-06-03 | 宾夕法尼亚州研究基金会 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
| US20070287680A1 (en) | 2004-05-10 | 2007-12-13 | University Of Utah Research Foundation | Combined Active and Passive Targeting of Biologically Active Agents |
| US7214664B2 (en) | 2004-12-03 | 2007-05-08 | The Curators Of The University Of Missouri | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux |
| CN101142210A (zh) * | 2005-01-26 | 2008-03-12 | 株式会社钟根堂 | 烟曲霉醇衍生物或制备烟曲霉醇衍生物的方法、以及包含该衍生物的药物组合物 |
| WO2006084054A2 (en) | 2005-02-02 | 2006-08-10 | Children's Medical Center Corporation | Method of treating angiogenic diseases |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| WO2006124711A1 (en) | 2005-05-16 | 2006-11-23 | The Board Of Trustees Of The University Of Illinois | Composition and method for providing localized delivery of a therapeutic agent |
| WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| JP2010531896A (ja) | 2007-06-26 | 2010-09-30 | チルドレンズ メディカル センター コーポレーション | 治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム |
| WO2009036108A1 (en) * | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
| US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
| EP2217283A2 (en) | 2007-11-28 | 2010-08-18 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| WO2009141826A2 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
| DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
| US20120004162A1 (en) * | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| TWI373345B (en) | 2009-02-19 | 2012-10-01 | Academia Sinica | Breast cancer-targeting peptides and use thereof |
| WO2011127304A2 (en) * | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| US20130137831A1 (en) | 2010-05-25 | 2013-05-30 | John S. Petersen | Optimized drug conjugates |
| DK2576638T3 (da) | 2010-05-25 | 2021-03-15 | Syndevrx Inc | Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| WO2012075020A1 (en) * | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
| WO2012122264A1 (en) * | 2011-03-08 | 2012-09-13 | Zafgen Corporation | Oxaspiro [2.5] octane derivatives and analogs |
| US9173956B2 (en) * | 2013-04-10 | 2015-11-03 | Syndevrx, Inc. | METAP2 inhibitors and methods of treating obesity |
| RU2017126206A (ru) | 2014-12-23 | 2019-01-25 | Маргарет Анне БРИМБЛЕ | Аминокислотные и пептидные конъюгаты и направления их использования |
| ES2893749T3 (es) | 2015-12-10 | 2022-02-10 | Syndevrx Inc | Derivados de fumagilol y polimorfos de los mismos |
| CA3008960C (en) | 2016-01-11 | 2024-07-02 | Syndevrx, Inc. | TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION |
-
2014
- 2014-04-09 US US14/248,787 patent/US9173956B2/en active Active
- 2014-04-09 JP JP2016507631A patent/JP6420314B2/ja active Active
- 2014-04-09 EP EP19185831.5A patent/EP3574922B1/en active Active
- 2014-04-09 CN CN202011226084.2A patent/CN112494476A/zh active Pending
- 2014-04-09 MX MX2015014329A patent/MX371095B/es active IP Right Grant
- 2014-04-09 AU AU2014250983A patent/AU2014250983B2/en active Active
- 2014-04-09 BR BR112015025892A patent/BR112015025892A2/pt not_active Application Discontinuation
- 2014-04-09 ES ES14782950T patent/ES2749746T3/es active Active
- 2014-04-09 EP EP14782950.1A patent/EP2984085B1/en active Active
- 2014-04-09 DK DK14782950.1T patent/DK2984085T3/da active
- 2014-04-09 ES ES19185831T patent/ES2902082T3/es active Active
- 2014-04-09 CN CN201480032972.7A patent/CN105431426A/zh active Pending
- 2014-04-09 CA CA2908993A patent/CA2908993C/en active Active
- 2014-04-09 MX MX2020000562A patent/MX386958B/es unknown
- 2014-04-09 DK DK19185831.5T patent/DK3574922T3/da active
- 2014-04-09 WO PCT/US2014/033476 patent/WO2014169026A1/en not_active Ceased
- 2014-04-09 EA EA201591943A patent/EA033912B1/ru unknown
-
2015
- 2015-09-11 US US14/851,668 patent/US9433600B2/en active Active
-
2016
- 2016-08-02 US US15/226,258 patent/US9750737B2/en active Active
- 2016-08-02 US US15/226,267 patent/US9757373B2/en active Active
-
2017
- 2017-08-01 US US15/665,755 patent/US10010544B2/en active Active
-
2018
- 2018-05-30 US US15/993,059 patent/US10588904B2/en active Active
- 2018-10-11 JP JP2018192578A patent/JP2019023219A/ja active Pending
-
2020
- 2020-01-27 US US16/752,908 patent/US11304944B2/en active Active
-
2021
- 2021-03-17 JP JP2021043481A patent/JP2021091738A/ja active Pending
-
2022
- 2022-02-28 US US17/682,165 patent/US20230048989A1/en not_active Abandoned
-
2023
- 2023-04-05 JP JP2023061783A patent/JP7681054B2/ja active Active
-
2025
- 2025-05-09 JP JP2025078682A patent/JP2025109807A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2022011I1 (no) | Tigolaner/Emodepsid/Praziquantel | |
| DK3574922T3 (da) | Modificerede eller polymerkonjugerede fumagillol-metap2-inhibitorer til anvendelse til forbedring eller reetablering af insulinfølsomhed | |
| DE202013012264U8 (de) | Druckempfindliches Trackpad | |
| EP2832811C0 (de) | Haftklebemasse | |
| DK2984138T3 (da) | Polymersammensætning | |
| EP2975043A4 (en) | Olefin-based polymer | |
| PL2831279T3 (pl) | Szybkie wykrywanie aneuploidii | |
| DK2970729T3 (da) | Klæbemiddelsammensætning | |
| DE112014001797A5 (de) | Fliehkraftpendel | |
| EP2999699A4 (en) | PURINE DIONES AS MODULATORS OF THE WNT PATH | |
| PL3036292T3 (pl) | Sposób wytwarzania polimerów emulsyjnych | |
| DK2981560T3 (da) | Hærdning af flydende termohærdende harpikser | |
| EP2886622A4 (en) | ADHESIVE COMPOSITION | |
| EP2889351A4 (en) | ADHESIVE COMPOSITION | |
| DK3024519T3 (da) | Destruktion af hypodermiske kanyler | |
| EP3012306A4 (en) | ADHESIVE COMPOSITION | |
| EP3012303A4 (en) | ADHESIVE COMPOSITION | |
| EP3012305A4 (en) | ADHESIVE COMPOSITION | |
| EP2805430A4 (en) | Codebook construction | |
| BR112015004238A2 (pt) | detectores de nível de líquido | |
| EP2986595A4 (en) | Epoxidation process | |
| DK2948143T3 (da) | Anvendelse af phenoxypropylaminforbindelser til behandling af depression | |
| EP2947129A4 (en) | ADHESIVE COMPOSITION | |
| PL3838877T3 (pl) | Mało wrażliwe materiały miotające | |
| DK2946359T3 (da) | Fremgangsmåde til evaluering af celleældning |